BR112022015666A2 - Vacinas intranasais de mrna - Google Patents
Vacinas intranasais de mrnaInfo
- Publication number
- BR112022015666A2 BR112022015666A2 BR112022015666A BR112022015666A BR112022015666A2 BR 112022015666 A2 BR112022015666 A2 BR 112022015666A2 BR 112022015666 A BR112022015666 A BR 112022015666A BR 112022015666 A BR112022015666 A BR 112022015666A BR 112022015666 A2 BR112022015666 A2 BR 112022015666A2
- Authority
- BR
- Brazil
- Prior art keywords
- mrna
- intranasal
- molecules
- antigens
- molecules encoding
- Prior art date
Links
- 108700021021 mRNA Vaccine Proteins 0.000 title abstract 3
- 229940126582 mRNA vaccine Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 108020004999 messenger RNA Proteins 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
VACINAS INTRANASAIS DE mRNA. A presente invenção em geral para vacinas intranasais de mRNA, mais em particular compreendendo uma ou mais moléculas imunoestimuladoras, um ou mais antígenos patogênicos e um sistema de distribuição especificamente projetado. Especificamente, referidas moléculas imunoestimuladoras e antígenos patogênicos são fornecidos sob a forma de moléculas de mRNA que codificam tais moléculas e antígenos; mais em particular, moléculas de mRNA que codificam CD40L, caTLR4 e/ou CD70 em combinação com uma ou mais moléculas de mRNA que codificam um antígeno bacteriano, viral ou fúngico. Especificamente referido, a distribuição é uma mistura de compostos químicos que permitem a proteção e a deposição da vacina e o direcionamento para o antígeno que apresenta células no nariz. Em particular, a presente invenção é bem adequada para o desenvolvimento de uma vacina de resposta rápida em um cenário de surto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157300 | 2020-02-14 | ||
| PCT/EP2021/053633 WO2021160881A1 (en) | 2020-02-14 | 2021-02-15 | Intranasal mrna vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015666A2 true BR112022015666A2 (pt) | 2022-09-27 |
Family
ID=69593570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015666A BR112022015666A2 (pt) | 2020-02-14 | 2021-02-15 | Vacinas intranasais de mrna |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230071518A1 (pt) |
| EP (1) | EP4103226A1 (pt) |
| JP (1) | JP2023518340A (pt) |
| KR (1) | KR20230004447A (pt) |
| CN (1) | CN115443148B (pt) |
| AU (1) | AU2021219304A1 (pt) |
| BR (1) | BR112022015666A2 (pt) |
| CA (1) | CA3170239A1 (pt) |
| IL (1) | IL295507A (pt) |
| MX (1) | MX2022009943A (pt) |
| TW (1) | TW202144002A (pt) |
| WO (1) | WO2021160881A1 (pt) |
| ZA (1) | ZA202209779B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
| US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2023037320A1 (en) * | 2021-09-10 | 2023-03-16 | Intron Biotechnology, Inc. | Mucosal messenger rna vaccine |
| WO2023108076A1 (en) * | 2021-12-08 | 2023-06-15 | Yale University | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| MX2016006134A (es) | 2013-11-12 | 2017-01-20 | Univ Brussel Vrije | Vector de transcripcion de arn y usos del mismo. |
| SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| IL266194B2 (en) * | 2016-10-26 | 2023-09-01 | Curevac Ag | mRNA vaccines with lipid nanoparticles |
-
2021
- 2021-02-15 IL IL295507A patent/IL295507A/en unknown
- 2021-02-15 CA CA3170239A patent/CA3170239A1/en active Pending
- 2021-02-15 WO PCT/EP2021/053633 patent/WO2021160881A1/en active Application Filing
- 2021-02-15 CN CN202180009112.1A patent/CN115443148B/zh active Active
- 2021-02-15 BR BR112022015666A patent/BR112022015666A2/pt unknown
- 2021-02-15 EP EP21705192.9A patent/EP4103226A1/en active Pending
- 2021-02-15 US US17/799,118 patent/US20230071518A1/en active Pending
- 2021-02-15 KR KR1020227031704A patent/KR20230004447A/ko unknown
- 2021-02-15 AU AU2021219304A patent/AU2021219304A1/en active Pending
- 2021-02-15 JP JP2022548838A patent/JP2023518340A/ja active Pending
- 2021-02-15 MX MX2022009943A patent/MX2022009943A/es unknown
- 2021-02-17 TW TW110105299A patent/TW202144002A/zh unknown
-
2022
- 2022-09-01 ZA ZA2022/09779A patent/ZA202209779B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103226A1 (en) | 2022-12-21 |
| JP2023518340A (ja) | 2023-05-01 |
| MX2022009943A (es) | 2022-10-18 |
| CN115443148B (zh) | 2024-08-06 |
| IL295507A (en) | 2022-10-01 |
| WO2021160881A9 (en) | 2022-11-10 |
| US20230071518A1 (en) | 2023-03-09 |
| CN115443148A (zh) | 2022-12-06 |
| TW202144002A (zh) | 2021-12-01 |
| WO2021160881A1 (en) | 2021-08-19 |
| CA3170239A1 (en) | 2021-08-19 |
| ZA202209779B (en) | 2024-01-31 |
| AU2021219304A1 (en) | 2022-10-06 |
| KR20230004447A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015666A2 (pt) | Vacinas intranasais de mrna | |
| Krammer et al. | Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | |
| Zhao et al. | Interferon induction of IFITM proteins promotes infection by human coronavirus OC43 | |
| Krammer et al. | H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge | |
| Rappazzo et al. | Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice | |
| Haye et al. | The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells | |
| Nogales et al. | Interplay of PA-X and NS1 proteins in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1 influenza A virus | |
| Rockman et al. | Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine | |
| Price et al. | Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model | |
| BR112019000015A2 (pt) | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos | |
| BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| BRPI0817299A8 (pt) | vacinas e componentes de vacina para inibição de células microbianas | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| Lara-Puente et al. | Safety and immunogenicity of a newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs | |
| AR068507A1 (es) | Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza | |
| Lorenzo et al. | Immunobiology of influenza vaccines | |
| CY1117896T1 (el) | Εμβολιο πρωτεϊνης συντηξης | |
| Turner et al. | Splenic priming of virus-specific CD8 T cells following influenza virus infection | |
| BR112015023886A2 (pt) | polipeptídeo, ácido nucleico, composição farmacêutica, e, método | |
| MX2022012251A (es) | Vacuna universal contra la influenza usando arnm modificado con nucleósidos. | |
| MacLeod et al. | Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence | |
| Zhang et al. | Broadly protective CD8+ T cell immunity to highly conserved epitopes elicited by heat shock protein gp96-adjuvanted influenza monovalent split vaccine | |
| BR112014003278A2 (pt) | vacinas para influenza h5 | |
| Bondareva et al. | Cross-regulation of antibody responses against the SARS-CoV-2 spike protein and commensal microbiota via molecular mimicry | |
| Sawai et al. | Induction of cytotoxic T‐lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin |